Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/28213
Title: Age and the Residual Risk of Cardiovascular Disease following Low Density Lipoprotein-Cholesterol Exposure
Authors: König, CS
Mann, A
McFarlane, R
Marriott, J
Price, M
Ramachandran, S
Keywords: mathematical modelling;residual cardiovascular risk;age and cardiovascular disease;low density lipoprotein cholesterol exposure;non-LDL-C cardiovascular risk factors
Issue Date: 2-Dec-2023
Publisher: MDPI
Citation: König, C.S. et al. (2023) 'Age and the Residual Risk of Cardiovascular Disease following Low Density Lipoprotein-Cholesterol Exposure',Biomedicines, 11 (12), 3208, pp. 1 - 13. doi: 10.3390/biomedicines11123208.
Abstract: We believe that there is sufficient evidence from basic science, longitudinal cohort studies and randomised controlled trials which validates the low-density lipoprotein cholesterol (LDL-C) or lipid hypothesis. It is important that we can communicate details of the cardiovascular disease (CVD) risk reduction that the average patient could expect depending on the scale of LDL-C decrease following lipid lowering therapy. It is also essential that residual risk (ResR) of CVD be highlighted. To achieve this aim by using existing trial evidence, we developed mathematical models initially for relative risk reduction (RRR) and absolute risk (AR) reduction and then showed that despite optimising LDL-C levels, a considerable degree of ResR remains that is dependent on AR. Age is significantly associated with AR (odds ratio: 1.02, 95% confidence intervals: 1.01–1.04) as was previously demonstrated by analysing the Whickham study cohort using a logistic regression model (age remaining significant even when all the other significant risk factors such as sex, smoking, systolic blood pressure, diabetes and family history were included in the regression model). A discussion of a paper by Ference et al. provided detailed evidence of the relationship between age and AR, based on lifetime LDL-C exposure. Finally, we discussed non-traditional CVD risk factors that may contribute to ResR based on randomised controlled trials investigating drugs improving inflammation, thrombosis, metabolic and endothelial status.
URI: https://bura.brunel.ac.uk/handle/2438/28213
DOI: https://doi.org/10.3390/biomedicines11123208
Other Identifiers: ORCID iD: Carola S König https://orcid.org/0000-0002-9289-3154
ORCID iD: Amar Mann https://orcid.org/0000-0002-7972-4794
ORCID iD: Rob McFarlane https://orcid.org/0009-0002-7895-4739
ORCID iD: Sudarshan Ramachandran https://orcid.org/0000-0003-2299-4133
3208
Appears in Collections:Dept of Mechanical and Aerospace Engineering Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).787.23 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons